Clinical Trial

Secondary Sclerosis Cholangitis Prospective

Study acronym: SSCpro
Recruiting
View on ClinicalTrials.gov →
Summary
SC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. Gut microbiome composition, gut permeability, bacterial translocation, inflammation and/or genetic variants contribute to the pathogenesis The aim of this project is to study gut microbiome composition, gut permeability, bacterial translocation, inflammation, bile acid composition and genetic polymorphisms by conducting a prospective cohort study in patients with a high risk to develop SC-CIP.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-06-21; most recent amendment 2024-10-07.
Status change: Not Yet Recruiting → Recruiting 2018-07-30
Trial Details
NCT Number NCT03566797
Lead Sponsor Medical University of Graz
Conditions Secondary Sclerosis Cholangitis in Critically Ill Patients
Enrollment 380 participants
Start Date 2018-07-20
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-09